Cephalexin for Cystic Fibrosis
Study Summary
This trial will test whether the antibiotic cephalexin can improve lung function in children with cystic fibrosis who have grown a specific type of bacteria.
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 2 & 3 trial • 2265 Patients • NCT00729937Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Has the FDA cleared Cephalexin for medical use?
"There is already some efficacy data for Cephalexin from Phase 3 trials, as well as multiple rounds of safety data, so it receives a score of 3."
How many people are allowed to join this trial?
"The information available on clinicaltrials.gov reveals that this trial is currently looking for individuals to participate. The study was first posted on 7/27/2020, and the most recent update was 1/12/2022. They are recruiting for 86 participants from 2 locations."
Is there still room for more people in this particular experiment?
"Yes, this trial is still recruiting patients. The study was posted on July 27th 2020 and updated January 12th of this year. They need 86 individuals total from 2 different locations."
Are there many peer-reviewed papers on Cephalexin's efficacy?
"There are currently 14 ongoing studies investigating Cephalexin. 3 of these trials have reached Phase 3 status. Most of the research being conducted on Cephalexin is based in Morgantown, West Virginia; however, there are 44 different locations where clinical trials for this medication are taking place."
Could I be a candidate for this research?
"This study is for 86 children and adolescents with cystic fibrosis (CF), aged 3 to 17 years. The CF participants should: a) weigh more than 10 kg; b) have had at least one airway culture positive for methicillin-sensitive Staphylococcus aureus(MSSA) in the past 24 months or on 10 of the most recent cultures, whichever is greater; and c) not have worse lower respiratory tract symptoms than at baseline for 28 days prior to randomization."
Does this research opportunity have an age limit?
"This study is available for children aged 3-17."
What are some common indications for Cephalexin?
"While most often used to treat streptococcus pneumoniae, cephalexin can also be administered to patients suffering from otitis media (om), genitourinary tract infection, and communicable diseases."